Cargando…

A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients

PURPOSE: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous according to the TNM staging system, they form a heterogeneous group, which is reflected in the survival outcome. The increasing amount of information for an individual patient and the growing number of trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Oberije, Cary, De Ruysscher, Dirk, Houben, Ruud, van de Heuvel, Michel, Uyterlinde, Wilma, Deasy, Joseph O., Belderbos, Jose, Dingemans, Anne-Marie C., Rimner, Andreas, Din, Shaun, Lambin, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786012/
https://www.ncbi.nlm.nih.gov/pubmed/25936599
http://dx.doi.org/10.1016/j.ijrobp.2015.02.048
_version_ 1782420485031591936
author Oberije, Cary
De Ruysscher, Dirk
Houben, Ruud
van de Heuvel, Michel
Uyterlinde, Wilma
Deasy, Joseph O.
Belderbos, Jose
Dingemans, Anne-Marie C.
Rimner, Andreas
Din, Shaun
Lambin, Philippe
author_facet Oberije, Cary
De Ruysscher, Dirk
Houben, Ruud
van de Heuvel, Michel
Uyterlinde, Wilma
Deasy, Joseph O.
Belderbos, Jose
Dingemans, Anne-Marie C.
Rimner, Andreas
Din, Shaun
Lambin, Philippe
author_sort Oberije, Cary
collection PubMed
description PURPOSE: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous according to the TNM staging system, they form a heterogeneous group, which is reflected in the survival outcome. The increasing amount of information for an individual patient and the growing number of treatment options facilitate personalized treatment, but they also complicate treatment decision making. Decision support systems (DSS), which provide individualized prognostic information, can overcome this but are currently lacking. A DSS for stage III NSCLC requires the development and integration of multiple models. The current study takes the first step in this process by developing and validating a model that can provide physicians with a survival probability for an individual NSCLC patient. METHODS AND MATERIALS: Data from 548 patients with stage III NSCLC were available to enable the development of a prediction model, using stratified Cox regression. Variables were selected by using a bootstrap procedure. Performance of the model was expressed as the c statistic, assessed internally and on 2 external data sets (n=174 and n=130). RESULTS: The final multivariate model, stratified for treatment, consisted of age, gender, World Health Organization performance status, overall treatment time, equivalent radiation dose, number of positive lymph node stations, and gross tumor volume. The bootstrapped c statistic was 0.62. The model could identify risk groups in external data sets. Nomograms were constructed to predict an individual patient’s survival probability (www.predictcancer.org). The data set can be downloaded at https://www.cancerdata.org/10.1016/j.ijrobp.2015.02.048. CONCLUSIONS: The prediction model for overall survival of patients with stage III NSCLC highlights the importance of combining patient, clinical, and treatment variables. Nomograms were developed and validated. This tool could be used as a first building block for a decision support system.
format Online
Article
Text
id pubmed-4786012
institution National Center for Biotechnology Information
language English
publishDate 2015
record_format MEDLINE/PubMed
spelling pubmed-47860122016-03-10 A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients Oberije, Cary De Ruysscher, Dirk Houben, Ruud van de Heuvel, Michel Uyterlinde, Wilma Deasy, Joseph O. Belderbos, Jose Dingemans, Anne-Marie C. Rimner, Andreas Din, Shaun Lambin, Philippe Int J Radiat Oncol Biol Phys Article PURPOSE: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous according to the TNM staging system, they form a heterogeneous group, which is reflected in the survival outcome. The increasing amount of information for an individual patient and the growing number of treatment options facilitate personalized treatment, but they also complicate treatment decision making. Decision support systems (DSS), which provide individualized prognostic information, can overcome this but are currently lacking. A DSS for stage III NSCLC requires the development and integration of multiple models. The current study takes the first step in this process by developing and validating a model that can provide physicians with a survival probability for an individual NSCLC patient. METHODS AND MATERIALS: Data from 548 patients with stage III NSCLC were available to enable the development of a prediction model, using stratified Cox regression. Variables were selected by using a bootstrap procedure. Performance of the model was expressed as the c statistic, assessed internally and on 2 external data sets (n=174 and n=130). RESULTS: The final multivariate model, stratified for treatment, consisted of age, gender, World Health Organization performance status, overall treatment time, equivalent radiation dose, number of positive lymph node stations, and gross tumor volume. The bootstrapped c statistic was 0.62. The model could identify risk groups in external data sets. Nomograms were constructed to predict an individual patient’s survival probability (www.predictcancer.org). The data set can be downloaded at https://www.cancerdata.org/10.1016/j.ijrobp.2015.02.048. CONCLUSIONS: The prediction model for overall survival of patients with stage III NSCLC highlights the importance of combining patient, clinical, and treatment variables. Nomograms were developed and validated. This tool could be used as a first building block for a decision support system. 2015-04-30 2015-07-15 /pmc/articles/PMC4786012/ /pubmed/25936599 http://dx.doi.org/10.1016/j.ijrobp.2015.02.048 Text en This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Oberije, Cary
De Ruysscher, Dirk
Houben, Ruud
van de Heuvel, Michel
Uyterlinde, Wilma
Deasy, Joseph O.
Belderbos, Jose
Dingemans, Anne-Marie C.
Rimner, Andreas
Din, Shaun
Lambin, Philippe
A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients
title A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients
title_full A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients
title_fullStr A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients
title_full_unstemmed A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients
title_short A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients
title_sort validated prediction model for overall survival from stage iii non-small cell lung cancer: toward survival prediction for individual patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786012/
https://www.ncbi.nlm.nih.gov/pubmed/25936599
http://dx.doi.org/10.1016/j.ijrobp.2015.02.048
work_keys_str_mv AT oberijecary avalidatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients
AT deruysscherdirk avalidatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients
AT houbenruud avalidatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients
AT vandeheuvelmichel avalidatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients
AT uyterlindewilma avalidatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients
AT deasyjosepho avalidatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients
AT belderbosjose avalidatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients
AT dingemansannemariec avalidatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients
AT rimnerandreas avalidatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients
AT dinshaun avalidatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients
AT lambinphilippe avalidatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients
AT oberijecary validatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients
AT deruysscherdirk validatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients
AT houbenruud validatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients
AT vandeheuvelmichel validatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients
AT uyterlindewilma validatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients
AT deasyjosepho validatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients
AT belderbosjose validatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients
AT dingemansannemariec validatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients
AT rimnerandreas validatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients
AT dinshaun validatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients
AT lambinphilippe validatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients